MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

2.21 3.76

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.11

Max

2.24

Chiffres clés

By Trading Economics

Revenu

53M

-46M

Ventes

-8.8M

56M

BPA

-0.02

Marge bénéficiaire

-82.429

Employés

570

EBITDA

127M

-21M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+157.41% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-66M

600M

Ouverture précédente

-1.55

Clôture précédente

2.21

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 avr. 2025, 23:55 UTC

Actions en Tendance

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 avr. 2025, 22:50 UTC

Principaux Mouvements du Marché

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 avr. 2025, 21:08 UTC

Résultats

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 avr. 2025, 21:00 UTC

Résultats

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 avr. 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 avr. 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2 avr. 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 avr. 2025, 23:44 UTC

Actualités

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 avr. 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 avr. 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 avr. 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 avr. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2 avr. 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 avr. 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 avr. 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 avr. 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 avr. 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 avr. 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 avr. 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 avr. 2025, 22:43 UTC

Actualités
Acquisitions, Fusions, Rachats

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 avr. 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 avr. 2025, 21:48 UTC

Actualités

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 avr. 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 avr. 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 avr. 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 avr. 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 avr. 2025, 21:04 UTC

Actualités

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 avr. 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 avr. 2025, 20:53 UTC

Résultats

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 avr. 2025, 20:52 UTC

Résultats

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

157.41% hausse

Prévisions sur 12 Mois

Moyen 5.56 USD  157.41%

Haut 10 USD

Bas 2.5 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

6

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

2.19 / 2.25Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Neutral Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.